UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

Clinical cancer research, 2017-08, Vol.23 (15), p.4441-4449

2017

Volltextzugriff (PDF)

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.383-383

2020

Volltextzugriff (PDF)

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.2-2

2017

Volltextzugriff (PDF)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Nature medicine, 2023-08, Vol.29 (8), p.2133-2141

2023

Volltextzugriff (PDF)

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-06, Vol.401 (10391), p.1853-1865

2023

Volltextzugriff (PDF)

Development of hand-food skin reaction correlates with prognosis of patients with HCC who were treated with sorafenib

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16171-e16171

2022

Volltextzugriff (PDF)

Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients

Clinical cancer research, 2015-01, Vol.21 (2), p.357-364

2015

Volltextzugriff (PDF)

Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells

Anticancer research, 2018-02, Vol.38 (2), p.787-794

2018

Volltextzugriff (PDF)

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4032-4032

2022

Volltextzugriff (PDF)

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Volltextzugriff (PDF)

Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW

Journal of clinical oncology, 2023-04, Vol.41 (36_suppl), p.405736-405736

2023

Volltextzugriff (PDF)

Abstract 899: Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.899-899

2018

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4003-4003

2023

Volltextzugriff (PDF)

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.550-550

2023

Volltextzugriff (PDF)

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4067-4067

2023

Volltextzugriff (PDF)

Abstract 5327: Glioma derived cancer stem cells are hypersensitive to proteasomal inhibition

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5327-5327

2017

Volltextzugriff (PDF)

Abstract 2254: Reactive oxygen species modulator 1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2254-2254

2017

Volltextzugriff (PDF)

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.160-160

2021

Volltextzugriff (PDF)

Interim analysis of fluorodeoxyglucose uptake in patients with metastatic or recurrent gastric cancer treated with fluoropyrimidine based chemotherapy

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.44-44

2015

Volltextzugriff (PDF)

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.TPS185-TPS185

2021

Volltextzugriff (PDF)

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS2656-TPS2656

2021

Volltextzugriff (PDF)

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4010-4010

2021

Volltextzugriff (PDF)

Abstract 102: RUNX3 inhibits invasiveness and stemness through downregulation of Gli-1 in colon cancer cells

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.102-102

2018

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Aktive Filter

ThemaAged

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(74)

Sprache

Englisch
(73)
Japanisch
(3)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data

Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Development of hand-food skin reaction correlates with prognosis of patients with HCC who were treated with sorafenib

Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients

Transglutaminase 2 Regulates Self-renewal and Stem Cell Marker of Human Colorectal Cancer Stem Cells

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW

Abstract 899: Phosphorylated mTOR by signaling through EphB3 confers resistance to a selective FGFR inhibitor in SNU-16 gastric cancer cells

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY

Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)

Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial

Abstract 5327: Glioma derived cancer stem cells are hypersensitive to proteasomal inhibition

Abstract 2254: Reactive oxygen species modulator 1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT)

Interim analysis of fluorodeoxyglucose uptake in patients with metastatic or recurrent gastric cancer treated with fluoropyrimidine based chemotherapy

Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress)

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC)

Abstract 102: RUNX3 inhibits invasiveness and stemness through downregulation of Gli-1 in colon cancer cells

Aktive Filter

Suchergebnisse filtern